Weekly update Companies AI-cruiter Recruiting service

Morphic Therapeutic

Founded: 2016

Location: Waltham, MA

Employee range: 50 - 200

Clinical stage: Clin2

Therapy area: Ulcerative colitis, Crohn's

Drug types: GI, ONC, CVV

Lead product: MORF-057

Product link: https://morphictx.com/pipeline/

Funding: $240M stock May 2023; $245M stock Mar 2021; $90M IPO Jun 2019; $80M B Sep 2018; $51.5M A Jul 2016

morphictx.com

linkedin.com

job board

Short description:

Oral Integrin Drugs

Drug notes:

4 undisclosed programs RD/Clin0 GI conditions, solid tumors, fibrotic conditions, PAH, undisclosed

Long description:

Morphic Therapeutic is developing a new generation of oral integrin therapies to treat autoimmune, cardiovascular and metabolic diseases. Integrins are receptors found at the cell membrane and are involved in many cellular processes by signaling bi-directionally. Malfunctions in the integrins are linked with disease. Using their proprietary MInT drug discovery platform and knowledge from integrin research leaders, Morphic is in the position to target all 24 known human integrins to stabilize their conformation or to activate or inhibit their activity to modify disease. One molecule (MORF-057) is already in Phase I clinical trials for inflammatory bowel disease.